Psoriasis News and Research

Latest Psoriasis News and Research

New understanding of genetic basis of psoriasis

Two international teams of researchers have made significant gains in understanding the genetic basis of psoriasis, a chronic skin condition that can be debilitating in some patients.

27 Jan 2009

Compromised skin barrier function plays a role in the development of psoriasis

Researchers at the Genome Institute of Singapore (GIS) and the Anhui Medical University, China, have identified genes that play an important role in the development of psoriasis, a common chronic skin disease.

27 Jan 2009

Online communities provide valuable support for psoriasis sufferers

Online support communities appear to offer both a valuable educational resource and a source of psychological and social support for individuals with psoriasis, according to a report in the January issue of Archives of Dermatology.

19 Jan 2009

Onyx Pharmaceuticals acquires license option on novel JAK2 inhibitors from S*BIO

Onyx Pharmaceuticals, Inc. has announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO Pte Ltd based in Singapore.

6 Jan 2009

FDA issues complete response to biologics license application for ustekinumab

Centocor, Inc., has announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its Biologics License Application (BLA) for ustekinumab.

21 Dec 2008

Patients with skin disease psoriasis need evaluation of coronary artery disease risk

According to new recommendations in the December 10 issue of The American Journal of Cardiology (AJC), published by Elsevier, new research is called for and patients with severe forms of the skin disease psoriasis should receive evaluation and possible treatment to reduce their risk of coronary artery disease (CAD).

18 Dec 2008

Psoriasis sufferers more likely to have higher levels of leptin

Patients with the skin disease psoriasis appear more likely to have higher levels of leptin (a hormone produced by fat cells that may contribute to obesity and other metabolic abnormalities) than persons without psoriasis, according to a report in the December issue of Archives of Dermatology.

15 Dec 2008

3.6 million Americans living with active, undiagnosed psoriasis, unaware of associated risks

Armed with research concluding that psoriasis is associated with an increased risk of heart attacks and other cardiovascular conditions, Joel M. Gelfand, MD, MSCE, Assistant Professor of Dermatology at the University of Pennsylvania School of Medicine and colleagues released an editorial consensus in the American Journal of Cardiology today¸ calling for psoriasis patients to be educated about and screened for cardiovascular risk factors.

15 Dec 2008

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Incyte Corporation will present updated results from an ongoing Phase II trial of INCB18424, its selective, orally available Janus kinase (JAK) inhibitor, in patients with myelofibrosis (MF) at the 50th American Society of Hematology (ASH) Annual Meeting.

8 Dec 2008

Tobacco plants grown in novel mist bioreactor system provide new soure of interleukin-12

Interleukin-12 is a naturally occurring protein essential for the proper functioning of the human immune system.

3 Dec 2008

MorphoSys granted U.S. patent on antibodies against GM-CSF to treat inflammatory disorders

MorphoSys AG and the University of Melbourne announced today that the U.S. Patent & Trademark Office (USPTO) has confirmed that it will issue U.S. Patent No. 7,455,836, covering key uses of antibodies against GM-CSF.

25 Nov 2008

Ustekinumab receives positive opinion in Europe for treatment of plaque psoriasis

Janssen-Cilag announced today that ustekinumab, the first in a new class of biologics, has received a positive opinion for the treatment of moderate to severe plaque psoriasis from the European Committee for Medical Products for Human Use (CHMP).

24 Nov 2008

Musculoskeletal Center wins $2.2 million to study biologics safety

The UAB Center for Education and Research on Therapeutics has won a $2.2 million federal grant to study the risks and benefits of a class of drugs called ‘biologics' -- genetically engineered agents targeting the immune system of patients with rheumatoid arthritis, Crohn's disease, psoriasis and other autoimmune disorders.

18 Nov 2008

Ointment made from indigo naturalis may help treat psoriasis

An ointment made from indigo naturalis, a dark blue plant-based powder used in traditional Chinese medicine, appears effective in treating plaque-type psoriasis, according to a report in the November issue of Archives of Dermatology.

17 Nov 2008

Xamiol gel provides relief for scalp psoriasis

A new, once-daily treatment gel is available on prescription today for the itching, flaking and soreness caused by the common condition scalp psoriasis.

10 Nov 2008

Systems biology and glycomics used to study human inflammatory diseases

An innovative systems biology approach to understanding the carbohydrate structures in cells is leading to new ways to understand how inflammatory illnesses and cardiovascular disease develop in humans. The work was described in two recent publications by University at Buffalo chemical engineers.

28 Oct 2008

Feeling itchy? it may be stress!

German and Canadian researchers are suggesting that stress may make people itch - they say stress possibly activates immune cells in the skin and inflames it.

27 Oct 2008

First-ever international guidelines for the treatment of psoriatic arthritis

Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it.

26 Oct 2008

FDA approves new labeling for psoriasis drug Raptiva

The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.

19 Oct 2008

Arana updates inflammatory pipeline milestones

Biotechnology company Arana Therapeutics Limited today provided an update on the major inflammatory compounds in its drug development pipeline. As part of this update, Arana said it has developed a new antibody candidate ART123, targeting inflammatory diseases and it plans to start a Phase I clinical trial for age-related macular degeneration (AMD) candidate PMX53 in 2009.

21 Sep 2008